In this review:
- Treatment rechallenge after trastuzumab deruxtecan-related ILD
- Vepdegestrant vs fulvestrant in ER-positive/HER2-negative advanced breast cancer
- INAVO120: Final overall survival analysis
- Fulvestrant + ipatasertib for advanced ER-positive/HER2-negative breast cancer
- Sacituzumab govitecan + pembrolizumab in PD-L1-positive advanced TNBC
- Trastuzumab deruxtecan + pertuzumab for first-line treatment of HER2-positive advanced breast cancer
- Adjuvant exemestane + OFS in premenopausal ER-positive early breast cancer
- Elinzanetant for VMS associated with adjuvant endocrine therapy
- ctDNA-guided detection of emerging resistance: SERENA-6 trial
Please login below to download this issue (PDF)